<DOC>
	<DOCNO>NCT00006120</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Randomized phase II trial compare effectiveness two different regimen docetaxel paclitaxel treat woman unresectable locally advanced metastatic breast cancer .</brief_summary>
	<brief_title>Docetaxel Paclitaxel Treating Women With Unresectable Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare response rate , progression free survival , overall survival woman unresectable locally advanced metastatic breast cancer treat two different schedule docetaxel paclitaxel . - Compare toxicity pharmacoeconomics four regimen patient . - Compare quality life patient treat four regimen . OUTLINE : This randomize , multicenter study . Patients stratify center , age , ECOG performance status , hormone receptor status ( positive v negative ) , metastasis liver ( yes v ) , presence disease progression follow anthracyclines ( yes v ) . Patients randomize one four treatment arm . - Arm I : Patients receive docetaxel IV 1 hour day 1 . - Arm II : Patients receive paclitaxel IV 3 hour day 1 . - Arm III : Patients receive docetaxel IV 1 hour day 1 , 8 , 15 , 22 , 29 , 36 . - Arm IV : Patients receive paclitaxel IV 1 hour day 1 , 8 , 15 , 22 , 29 , 36 . Courses repeat every 3 week ( arm I II ) every 8 week ( arm III IV ) absence disease progression unacceptable toxicity . Quality life assess prior treatment every 8 week . PROJECTED ACCRUAL : A total 165 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven unresectable locally advanced metastatic breast cancer Refractory relapse disease neoadjuvant adjuvant anthracyclines At least one bidimensionally measurable lesion No brain metastasis No bone metastasis , lymphangitis carcinomatous , ascites , pleural effusion sole site metastatic disease Hormone receptor status : Known hormone receptor status PATIENT CHARACTERISTICS : Age : 18 75 Sex : Female Menopausal status : Not specify Performance status : ECOG 02 OR Karnofsky 60100 % Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : AST ALT great 2.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN Bilirubin normal Renal : Creatinine great 1.5 time ULN Cardiovascular : No uncontrolled angina arrhythmia No myocardial infarction within past 6 month No New York Heart Association class III IV heart disease Other : No sensitive neuropathy bad grade 2 No significant , uncontrolled medical psychiatric condition No serious active infection Not pregnant nursing Fertile patient must use effective contraception No prior malignancy except treat nonmelanomatous skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior specific antitumoral immunotherapy Chemotherapy : See Disease Characteristics No prior taxanes At least 4 week since prior specific antitumoral chemotherapy Endocrine therapy : At least 4 week since prior specific antitumoral hormonal therapy Radiotherapy : At least 4 week since prior specific antitumoral radiotherapy Surgery : Not specify Other : No concurrent experimental medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>